Maze Therapeutics, Inc. Common Stock logo

Maze Therapeutics, Inc. Common Stock (MAZE) Q1 2026 Earnings

MAZE·Reported May 12, 2026·Before market open

Maze Therapeutics, Inc. Common Stock reported Q1 2026 revenue of $20.0M, beat analyst consensus of $10.6M by $9.4M. Diluted EPS came in at $-0.45 (+60.9% YoY), missed the $-0.43 consensus by $0.02.

Revenue
$20.0Mbeat by $9.4M
Consensus: $10.6M
Diluted EPS
$-0.45missed by $0.02
Consensus: $-0.43
SEC

SEC Filings

Earnings release8-K · 0001193125-26-219398
Quarterly report10-Q · 0001193125-26-219430

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Maze Therapeutics, Inc. Common Stock's Q1 2026 earnings report.

Maze Therapeutics, Inc. Common Stock (MAZE) reported Q1 2026 earnings on May 12, 2026 before market open.

Maze Therapeutics, Inc. Common Stock reported revenue of $20.0M and diluted EPS of $-0.45 for Q1 2026.

Revenue beat the consensus estimate of $10.6M by $9.4M. EPS missed the consensus estimate of $-0.43 by $0.02.

Compared to the same quarter a year prior, diluted EPS grew 60.9% from $-1.15.

You can read the 8-K earnings release (0001193125-26-219398) and the 10-Q periodic report (0001193125-26-219430) directly on SEC EDGAR. The filing index links above go to sec.gov.